Q-omics provides the consensus-scored COL11A2 profile across patient tissues and cancer cell-line models. COL11A2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, COL11A2 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, COL11A2 RNA expression shows 16,468 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KICH, and THYM as cancer lineages where COL11A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COL11A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COL11A2 survival associations across molecular data types. COL11A2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COL11A2 RNA expression–survival associations across cancer types. High COL11A2 expression shows unfavorable associations in COAD, ACC, KIRP, MESO and SCLC, but favorable associations in UVM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for COL11A2 RNA expression.
This table summarizes COL11A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for COL11A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COL11A2 shows lower tumor expression in KICH and BRCA and higher tumor expression in UCEC, CHOL, BLCA and LUSC. The KICH box plot shows higher COL11A2 RNA expression in normal versus tumor tissue (log2 FC = −0.440, t-test p < 0.001).
This table shows molecular features associated with COL11A2 in patient tissues and cancer cell lines. In patient samples, COL11A2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, COL11A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
